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Ah&r-a&-The effects of the iron chelator desferrioxamine (DFx) on liver iron accumulation, malon- 
dialdehyde (MDA) production, porphyrin accumulation and uroporphyrinogen decarboxylase (URO- 
D; EC 4.1.1:37) activity were investigated over a period of 14 weeks in C57BL/lO mice, made porphyric 
bv the administration of hexachlorobenzene (HCB) and iron-dextran (Imferon, IMF) or IMF alone. In 
addition, we measured the amount of low molecular weight (LMW) iron in liver tissue to determine a 
possible correlation with MDA production. These experiments howed that combined treatment with 
HCB + IMF, as well as IMF alone, resulted in porphyrin accumulation, increased MDA production 
and reduced URO-D activity, whereas HCB alone had no effect. DFx caused a reduction in hepatic 
porphyrins, this reduction being more distinct in the IMF group than in the HCB + IMF group. The 
effect of DFx on MDA production and URO-D activity was in agreement with the results on porphyrin 
accumulation. LMW iron pool measurements at11 weeks correlated well with data on MDA production 
in all treated groups in that period ,(r2 = 0.84), suggesting both variables are interdependent. In 
conclusion, these results suggest an important role for iron in porphyrin accumulation, probably through 
its catalytic role in the generation of oxygen-related free radicals, resulting in direct damage to URO- 
D. The effectiveness of DFx in reducing porphyrin accumulation is probably the result of a reduction 
in LMW iron, thus diminishing the amount of iron available for a catalytic role in the generation of 
oxygen-related free radicals. 
Both experimental uroporphyria and human por- diminishes or completely prevents the development 
phyria cutanea tarda are characterized by a partial of porphyria in animals [6,8,15,16]. The effect of 
block in the haem biosynthetic pathway at the level 
of uroporphyrinogen decarboxylase (URO-D;Q EC 
iron has been explained by its ability to participate 
in iron-catalysed free radical-mediated processes 
4.1.1.37) and by the accumulation of uroporphyrins 
and heptacarboxylporphyrins in the liver [l]. 
[8,10,11,17-19). If in hepatocytes, either as a result 
of cytochrome P450 induction or as a result of 
Uroporphyria can be induced in rodents and humans 
by the administration of hexachlorobenzene (HCB), 
(genetically determined) active oxidative metabolism 
a polyhalogenated aromatic hydrocarbon [2]. 
in certain species, reactive oxygen species are 
produced and “free” iron is also present, highly 
As in human porphyria cutanea tarda, iron plays reactive oxygen-related free radicals could be formed 
an important role in polyhalogenated aromatic by the Haber-Weiss reaction [20,21]. In addition, 
hydrocarbon-induced porphyria; porphyria develops 
faster if animals are made siderotic [3-121. In 
the intracellular presence of free ferrous iron itself 
can induce the formation of 0~ (superoxide) [22,23] 
addition the administration of Imferon (IMF), an and thus initiate the chain of reactions leading to 
iron-dextran complex, to C57BL/lO mice, by itself the formation of oxygen-related free radicals. In the 
leads to porphyrin accumulation [RI-121. Iron presence of oxygen-related free radicals a variety of 
deficiency due to bleeding [S] or treatment with reactions could be initiated, such as the peroxidation 
desferrioxamine (DFx) [13,14], an iron chelator, of membrane lipids [24]. Recently, we suggested 
that the process of lipid peroxidation is involved in 
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production (as a marker of lipid peroxidation), 
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dialdehyde; URO-D, uroporphyrinogen decarboxylase; course of time has not been studied extensively, we 
HCB, hexachlorobenzene; IMF, iron-dextran; LMW, low decided to investigate this in livers of C57BL/lO 
molecular weight. mice, made porphyric by the administration of 
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HCB + IMF or IMF alone. The nature of the iron 
pool involved in experimental porphyria is not clear. 
On the basis of the finding of a morphological co- 
occurrence of uroporphyrin crystals and ferritin iron 
in hepatocytes of porphyric C57BL/lO mice, we 
suggested a role for ferritin-bound iron in the 
pathogenesis of experimental porphyria [ 121. 
However, ferric iron in ferritin is sequestered in a 
non-toxic oxyhydroxide, complexed with phosphate. 
The release of iron from ferritin requires reduction 
[25]. Although in vitro release of ferrous iron from 
ferritin by liver microsomes has been described 
[9,26-291, it is not clear whether this also occurs in 
vivo. An alternative possibility is an intracellular 
pool of low molecular weight (LMW) iron, as 
suggested by Jacobs [30] and others [31-331. A role 
for this LMW iron has been demonstrated in free 
radical formation in iron-loaded cells [23,34,35]. A 
recently developed technique [35] to measure the 
amount of LMW iron in tissue homogenates was 
used to elucidate this problem further. 
MATERIALS AND METHODS 
Chemicals. HCB was purchased from Merck AG 
(Darmstadt, Germany), ferrihydroxide-dextrane 
(IMF) was purchased from Fisons Pharmaceuticals 
(Leusden, The Netherlands), Ethrane (Enfluraan) 
was purchased from Abbott B.V. (Amstelveen, The 
Netherlands) and deferoxaminmesilate (Desferal) 
was purchased from Ciba-Geiby B.V. (Arnhem, The 
Netherlands). All other chemicals were of the highest 
purity commercially available. 
Animals and treatment. This study was performed 
in accordance with the “Regulations for the use of 
laboratory animals at the Erasmus University 
Rotterdam”, laid down by the Laboratory Animal 
Committee of the Erasmus University. Male C57BL/ 
10 mice, 9-11 weeks of age and weighing 20-25 g, 
were purchased from Centraal Proefdier Bedrijf 
(Zeist, The Netherlands). 
HCB treatment consisted of two intraperitoneal 
(i.p.) injections of 8 mg HCB (400mg/kg body 
weight) dissolved in 0.25 mL warm corn oil, with 1 
week interval. Mice treated with IMF received a 
single i.p. injection of 12 mg (600mg/kg body 
weight). 
Treatment with DFx consisted of daily i.m. 
injections of 5 mg DFx (250 mg/kg body) in 0.05 mL 
sterile water, administered alternately to the hind 
legs. When both HCB and IMF were given, IMF 
was given 3 days after the second injection of HCB. 
HCB and IMF were injected under Ethrane 
anaesthesia. 
Twenty mice were given HCB alone (HCB), 
25 mice the combination of HCB and IMF 
(HCB + IMF) and 25 mice IMF alone (IMF). 
DFx administration started either immediately 
(HCB + IMF + DFx; 25 mice and IMF + DFx; 25 
mice) or at 7 weeks (HCB + IMF + DFx7; 15 mice 
and IMF + DFx7; 15 mice) to provide information 
on the effectiveness of DFx in reversing the changes 
induced by IMF and/or HCB. Twenty mice were 
not treated at all and served as controls (control 
group). 
In order to obtain blood-free livers, mice were 
anaesthetized with Ethrane, the vena cava inferior 
was cannulated and the liver was perfused with a 
0.15 M NaCl solution at room temperature until the 
fluid leaving the liver was clear (the average perfusion 
time was 3 min). Livers were removed, weighed and 
processed for further measurements. Measurements 
were performed before treatment (0 weeks) and at 
4, 7, 11 and 14 weeks after treatment with HCB and 
IMF and with IMF alone. 
Hepatic porphyrins. These were measured using 
a modification of the method described by Lim et 
al. [36]. Briefly, 300mg of liver tissue were 
homogenized (glass on glass, manual) to yield a 10% 
homogenate in water, which was then centrifuged 
at 10,000 g for 4 min. The supernatant was stored at 
-20” until further processing. To 0.1 mL of the 
homogenate, 0.1 mL of Tris-HCl (50 mmol/L, 
pH8.0) and 0.8 mL of a “mix” were added. 
The “mix” contained: 25 mL dimethyl sulphoxide 
(100% w/v), 10mL trichloric acid (50% w/v), 
10 mL HCI (1 mol/L),p-Benzoquinon (2.3 mmol/L) 
(Merck-Schuchandt, Hohenbrunn, Germany) [37] 
and 35 mL of distilled water. This was stirred and 
centrifuged for 15 min at 18OOg. The porphyrins in 
the supernatant were measured by reversed-phase 
HPLC [37]. Protein was measured according to 
Lowry et al. [38], and the amount of porphyrins 
expressed in picomoles per milligram protein. 
Hepatic URO-D activity. To 0.1 mL of a lU% 
homogenate of liver tissue (as described above), 
0.05 mL of DL-dithiothreitol (30 mmol/L) in Tris- 
HCl (50 mmol/L, pH 8.0) (Sigma Chemical Co., St 
Louis, MO, U.S.A.) was added to restore the activity 
of the enzyme uroporphyrinogen-III-synthase (EC 
4.2.1.75) [37], followed by incubation for 30 min at 
4”. Then, 0.05mL of porphobilinogen (0.8mg) in 
5 mL of EDTA (4 mmol/L) in Tris-HCI (50 mmol/ 
L, pH 8.0) was added, or followed by incubation for 
60min at 37” [39]. The reaction was stopped by 
adding 0.8 mL of the “mix” (as described above). 
This was stirred and centrifuged for 15 min at 1800 g. 
The porphyrins in the supernatant were measured 
by reversed-phase HPLC [36]. Protein was measured 
according to Lowry et al. [38] and the amount of 
porphyrins formed was expressed in picomoles per 
milligram protein. 
Total liver iron content. This was measured by a 
modification [ 121 of the method described by Harris 
[40]. Liver tissue was dried at 110” overnight. The 
dried liver tissue was weighed, 0.5 mL perchloric 
acid (70% w/v) was added and the solution was 
heated until colourless. After cooling, distilled water 
was added to a final volume of 2.0 mL. From this 
solution 0.2 mL was taken and 0.1 mL HCI (1 mol/ 
L), 0.2mL t-ascorbic acid (O.l4mol/L), 0.1 mL 
sodium acetate (saturated) and 0.2 mL Ferrozine 
(10 mmol/L) (Sigma) were added. This solution was 
mixed thoroughly and after 10 min the absorbance 
was measured at 562 nm against three standard iron 
solutions. The amount of iron was expressed in 
micromoles per gram dry weight. 
Total protein measurements [41]. A small sample 
of liver tissue was homogenized (Ultrathurax, Janke 
and Kunkel, Germany), followed by stepwise 
dilution. To 1OOpL of the 0.1% homogenate, 5 mL 
of Coomassie brilliant blue was added and after 
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10 min the absorbance was measured at 595 nm. The 
results were compared with four different standard 
solutions of bovine serum albumin (Pierce, Rockford, 
IL, U.S.A.) in the range of 100-4OO~g/mL. The 
amount of protein was expressed in micrograms per 
gram wet weight. 
MDA. This was measured using the method 
described by Kombrust and Mavis [42] and Wilson 
et al. [43]. Four aliquots (0.25,0.5,0.75 and 1.0 mL) 
of a 10% (wet w/v) liver tissue homogenate in a 
KCl/Tris-HCl buffer (0.15 mol/L, 5 mmol/L, pH = 
7.8) were filled up to a final volume of 1.0 mL with 
the same buffer solution. To each of these samples, 
0.3 mL trichloric acid (20% v/v), 0.6mL 2- 
thiobarbituric acid (0.05 mol/L) and 0.1 mL 2,6 di- 
tert-butyl-4-methylphenol (BHT) (0.2% in ethanol, 
w/v) were added. The solution was mixed and 
centrifuged (10 min, 2800g). The supernatant was 
heated for 8 min at 100” and immediately cooled. 
Subsequently, the absorbance was measured 
(535 nm, E = 156,000) and the results were compared 
to a standard solution of MDA, treated in the same 
manner. 
5 mL distilled water. In this way ferrioxamine (Fx) 
and DFx were retained, while most other compounds 
were eluted. Fx and DFx were subsequently eluted 
from the SEPPAK with 1 mL methanol and the 
effluent was applied to a HPLC RP 18 column 
(250 x 4 mm i.d., Merck). The mobile phase 
consisted of Na2HP04/NaH2POb, acetonitrile (88%, 
20 mmol/L, 12%), sodium-EDTA (2 mmol/L) and 
ammonium acetate (1 mol/L). HPLC analysis was 
performed on a dual pump LKB system with 
automatic sample injector and two variable wave- 
length detectors, to measure Fx (430 nm) and DFx 
(229 nm) simultaneously in the effluent. The results 
(duplicate samples, 4-fold measurements per sample) 
were compared to three standard amounts of iron, 
treated in the same manner as the liver samples. 
LMW iron. Amounts of LMW iron were measured 
after 11 weeks of treatment, by a method developed 
by Voogd er al. [35]. Some modifications were 
necessary, due to the limited quantity of liver tissue 
available for analysis. 
Statistical data analysis. All measurements are 
presented as means f SD. Differences within and 
between groups were evaluated by one-way analysis 
of variance. As multiple groups were compared, we 
used a one-way analysis procedure with a Bonferroni 
correction option in STATA release 2 (Computing 
Resource Center, Los Angeles, CA, U.S.A.). 
Results were considered significant if P < 0.05. 
RESULTS 
Total liver iron content (Fig. 1) 
A 10% (w/v) liver homogenate in Tris-HCl The liver iron content in the IMF group was 
(100 mmol/L, pH 7.4) was centrifuged for 15 min at significantly increased at 4 weeks, but even in the 
lO,ooOg, 0”). To 1 mL of the supernatant, 1OOpL following 10 weeks a distinct rise could be measured. 
DFx (22 mmol/L) were added and the samples were Liver iron content in the IMF + DFx group was 
incubated for 5, 15, 30 and 60 min at 37”. To stop significantly lower at all times, compared to the IMF 
the reaction between the available iron and DFx, group (P<O.OOl). In the IMF + DFx7 group, 
samples were passed through a SEPPAK Cl8 liver iron content decreased after starting DFx 
cartridge(MilliporeCorp.,Milford,U.S.A.)immedi- administration at 7 weeks, resulting in about a 50% 
ately after incubation. Prior to use, the cartridges liver iron reduction at 14 weeks. The increase in 
were conditioned by means of pre-elution with 5 mL liver iron content in the HCB + IMF group was 
methanol, followed by 5 mL distilled water. After equal to that in the IMF group. However, in the 
adding the samples, cartridges were flushed with HCB + IMF + DFx group, liver iron contents were 
5 10 
Treatment ime In week8 
Fig. 1. Liver iron concentration during the experimental period. Iron concentrations were measured in
duplicate samples of liver tissue of C57BL/lO mice. Open circles: control group. Open triangles: IMF 
group. Closed triangles: IMF + DFx group. Open squares: HCB + IMF group. Closed squares: 
HCB + IMF + DFx group. Closed diamonds: IMF + DFx7 group. Values shown represent the 
means f SD. 
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5 10 
Treatment time In weeks 
Fig. 2. Liver MDA concentration during the experimental period. MDA concentrations were measured 
4-fold in samples of liver tissue of C57BL/lO mice. Open circles: control group. Closed circles: HCB 
group. Open triangles: IMF group. Closed triangles: IMF + DFx group. Open squares: HCB + IMF 
group. Closed squares: HCB + IMF + DFx group. Values shown represent he means 2 SD. 
significantly elevated at all times, compared to the DFx. In the IMF + DFx group, MDA production 
iron results in the IMF + DFx group (P = 0.008). In at 14 weeks was even lower than that in the control 
contrast, liver iron content in the non-treated control 
mice was very low, with an average of 3 pmol/g dry 
groups. Treatment with HCB + IMF resulted in 
higher MDA concentrations than treatment with 
wt liver tissue. IMF alone; DFx reduced these differences. 
Liver MDA concentration (Fig. 2) Total liver porphyrins (Fig. 3) 
In all treated groups the highest MDA contents 
were found after 4 weeks of treatment, followed by 
a reduction in liver MDA, depending on the nature 
of the treatment. All DFx-treated groups showed a 
distinct reduction in MDA production compared to 
those groups receiving the same treatment without 
Significant porphyrin accumulation was not 
detected during the experimental period in livers of 
the control group, nor in livers of the HCB group. 
The IMF group showed a continuous increase in 
hepatic porphyrin accumulation during the 14 weeks. 
Apart from the results at 14 weeks, the hepatic 
2000 
5 10 
Treatment time In works 
Fig. 3. Liver porphyrin accumulation during the experimental period. Porphyrin concentrations were 
measured as described in Materials and Methods. Open circles: control group. Open triangles: IMF 
group. Closed triangles: IMF + DFx group. Open squares: HCB + IMF group. Closed squares: 
HCB + IMF + DFx group. Closed diamonds: IMF + DFx7 group. Values shown represent the 
means f SD. 
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5 10 
Troatmont tlmo In work8 
Fig. 4. Liver URO-D activities during the experimental period. URO-D activities were measured as 
described in Materials and Methods and expressed as percentages of activity of the control group 
(100%: 161 pmol/hr/mg protein). Open circles: control group. Open triangles: IMF group. Closed 
triangles: IMF + DFx group. Open squares: HCB + IMF group. Closed squares: HCB + IMF + DFx 
group. Closed diamonds: IMF + DFx7 group. Values shown represent the means f SD. 
porphyrin concentration in the HCB + IMF group 
was significantly higher than in the IMF group 
(P < 0.001). The reduction in porphyrin accumu- 
lation was more pronounced in livers of the 
IMF + DFx group than in the HCB + IMF + DFx 
group. 
Liver URO-D activities 
Apart from livers in the control group, a strong 
negative correlation (-0.80 to -0.92) was found 
between porphyrin accumulation and URO-D 
activity data in all treated groups. Liver URO-D 
activity showed an increase at 14 weeks in the 
IMF + DFx and IMF + DFx7 group. In the first 4 
weeks, URO-D activity in all HCB + IMF treated 
groups diminished to + 15% of control group values 
and did not recover during the latter part of the 
experimental period (Fig. 4). 
LMW iron pool content (Fig. 5) 
The results on LMW iron pool content at 11 weeks 
were compared with data on MDA production 
around that time. Calculations yielded a correlation 
coefficient of 0.84, thus indicating that the two 
variables are interdependent. 
DISCUSSION 
In accordance with previous tudies, we confirmed 
300 
LMW pool iron in nmolea/gm w.w. liver 
Fig. 5. Liver LMW pool iron concentrations compared to liver MDA concentrations after 11 weeks of 
treatment. Results of LMW iron pool measurements after 11 weeks were compared to MDA 
concentration results from that period. Open circles represent individual results. Calculations yielded 
a correlation coefficient of 0.34. 
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that treatment of C57BL/lO mice with HCB and IMF + DFx group [55 + 12.6 nmol/g wet wt liver 
IMF, but also with IMF alone, resulted in the tissue (mean + SD)] were also lower than those in 
accumulation of (uro)porphyrins in the liver. In this the IMF group (120.8 ? 15.1 nmol/g wet wt) and 
Strain of mice, HCB alone did not produce confirmed our data on MDA production (Fig. 5). 
uroporphyria [lo-121. These results (amongst others) These results support the theory of URO-D 
point to an important role for iron in the pathogenesis inactivation as a result of free radical-mediated 
of this form of uroporphyria. damage. 
Three major mechanisms for the role of iron in 
experimental uroporphyria have been proposed. (i) 
Iron (Fez’) binds directly to one or more sulfhydryl 
groups of URO-D [44-46]. This would inactivate 
the enzyme, which needs free sulfhydryl group(s) 
for its catalytic activity [44,47]. When (under aerobic 
conditions) URO-D is incubated with iron in the 
presence of an electron donor, a reduction in enzyme 
activity can be measured [44]. (ii) This could be the 
result of free radical-mediated damage to URO-D 
itself [44], or (iii) the result of oxidation of 
uroporphyrinogens to uroporphyrins that inhibit 
enzyme activity [ll, 15,481. 
In general, it is not clear whether the direct 
interaction of ferrous iron and URO-D also occurs 
in vivo. Mukerji et al. [44,45] found that Fez+ 
concentrations in the range of 0.1-1.0 mM were 
required in vitro to reduce the activity of 
partially purified URO-D. In our view, these Fez+ 
concentration requirements cannot be met in udvo 
[49]. However, our experimental results do not 
preclude the possibility of direct interaction between 
ferrous iron and URO-D. In fact, we found that 
IMF alone reduced URO-D activity and caused 
concomitant porphyrin accumulation. The relatively 
slow onset of porphyrin accumulation (as compared 
to the rapid accumulation of iron, cf. Fig. 1 to Fig. 
3) could be explained by the results of a morphological 
examination of the liver tissue of IMF-treated mice 
[50]. Iron-positive granules were present in Kupffer 
cells shortly after administration of IMF, but it took 
another 2 weeks before iron accumulation could be 
detected in the hepatocytes. As a rule, the 
accumulation of ferritin iron preceded porphyrin 
accumulation in hepatocytes [50]. Liver iron 
measurements do not detect this intraheptatic “iron 
shift” and give the sum of the iron content of both 
cell types. Therefore, these results are not an actual 
representation of the amount of iron accumulated in 
hepatocytes. Experimental results in the IMF + DFx 
group, however, partially contradict the possible 
interaction of ferrous iron and URO-D. At 14 weeks, 
URO-D activity was completely restored and 
accumulated porphyrins had disappeared, despite 
the fact that the liver iron concentration was still 10 
times higher than in the control group. 
In recent years, there has been a growing interest 
in the role of iron and other trace metals as mediators 
in the production of oxygen-related free radicals. In 
our experiments, treatment with IMF resulted in 
increased MDA production, which was maximal at 
4 weeks, but was still significantly increased at 14 
weeks (P = 0.004, Fig. 2), despite the fact that most 
iron will be stored in ferritin by this time. MDA 
production at 14 weeks in the IMF + DFx group is 
significantly lower than in the IMFgroup (P < 0.001). 
This could explain why URO-D activity was restored 
at that time, despite the presence of an iron excess 
in the liver. Moreover, the LMW iron results in the 
HCB causes the induction of microsomal cyto- 
chrome P450IA2 151,521 and this enzyme could 
promote oxidation of uroporphyrinogens: However, 
it is more likely that cytochrome P450IA2 induction 
leads to the generation of reactive oxygen species 
[21,53]. HCB alone did not induce porphyrin 
accumulation in C57BL/lO mice [12], neither did it 
affect MDA production. Combined treatment with 
HCB + IMF, however, resulted in increased MDA 
production, porphyrin accumulation and decreased 
URO-D activity as compared to the IMF group (Fig. 
2). These differences between the IMF and 
HCB + IMF groups were statistically significant for 
all results except those at 14 weeks (P < 0.004). In 
contrast, liver iron measurements (Fig. 1) as well as 
morphological studies [50] showed more or less equal 
results in both groups. The effects of DFx in the 
HCB + IMF + DFx group were less pronounced 
than in the IMF + DFx group as compared to their 
non-DFx treated counterparts. Still, the results at 
14 weeks in the HCB + IMF + DFx group are 
significantly different from those in the HCB + IMF 
group (P = 0.008), with the exception of the results 
on URO-D activity. In Fig. 4 it appears that URO- 
D activity in the HCB + IMF + DFx group increases, 
but measurements over a longer period of time will 
be necessary to confirm this trend. Our results 
support the idea that HCB stimulates the production 
of oxygen free radicals in the presence of iron. This 
is further illustrated by the fact that HCB alone will 
not induce porphyria in C57BL/lO mice, probably 
due to the very low levels of total liver iron in the 
non-treated animals [5,7,54]. In our view, DFx 
reduces the amount of iron available for a catalytic 
role in the generation of oxygen free radicals. Our 
data on LMW iron are in agreement with this theory: 
treatment with HCB + IMF resulted in a 50% 
increase in LMW iron (189.6 2 14.5 nmol/g wet wt 
liver tissue) as compared to IMF-treated mice. DFx 
reduced LMW iron in the HCB + IMF + DFx group 
(135.5 * 8.5 nmol/g wet wt), which is confirmed by 
our data on MDA and porphyrin accumulation. The 
discrepancy in LMW iron between the IMF and 
HCB + IMF groups could be the result of a reductive 
release of iron from ferritin, due to the generation 
of 02 by HCB [26,27]. Whether radical-mediated 
processes damage URO-D itself, or cause the 
oxydation of uroporphyrinogens, is still an open 
issue, as our porphyrin measurements do not 
discriminate between porphyrins and porphy- 
rinogens. However, the results on porphyrin 
accumulation and URO-D activity in the 
HCB + IMF + DFx group at 14 weeks are indicative 
of direct damage to URO-D, for the amount 
of porphyrins is already significantly diminished 
(P < 0.001) whereas URO-D activity is only slightly 
increased as compared to the results at 7 weeks (Figs 
3 and 4). 
In general, there seems to be a discrepancy 
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between the results on MDA production and iron 
a~umulation. After 4 weeks MDA production 
decreased, while iron was still accumulating in the 
hepatocytes. Iron storage in ferritin reduces the 
availability of catalytic iron for the generation of 
oxygen free radicals [25]. Ferritin synthesis is an 
iron-~gulated process at the mRNA level [SS] and, 
as mentioned before, morphological studies show 
that transport of iron from the injection site to the 
hepatocytes takes a considerable amount of time. 
Once iron reaches the hepatocytes, ferritin synthesis 
will be stimuiated, but it is reasonable to assume 
that ferritin synthesis will not be able to accommodate 
this iron excess immediately. Eventually, most iron 
will be stored in ferritin, but in the meantime the 
amount of “free” iron (LMW iron) will probably be 
elevated and enhance the generation of oxygen free 
radicals. 
We therefore conclude that iron is an important 
factor in porphyrin accumulation in C57BL/lO, 
probably through its catalytic role in the generation 
of oxygen-related free radicals, resulting in direct 
damage to URO-D. The possible direct interaction 
between iron and URO-D, rendering the enzyme 
inactive, cannot be excluded, but seems hardly likely 
with regard to the very high iron concentrations 
necessary for this inactivation to occur. DFx’s 
effectiveness in reducing porphyrin accumulation is 
most likely the result of a reduction in LMW iron, 
thus diminishing the amount of iron available for a 
catalytic role in the generation of oxygen-related 
free radicals. 
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